Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
- Registration Number
- NCT00292526
- Lead Sponsor
- European Institute of Oncology
- Brief Summary
In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 114
Inclusion Criteria
- Consecutive patients undergoing high-dose chemotherapy showing early release of Troponin I
Exclusion Criteria
- Contraindication to ACE-inhibitors
- On-going therapy with beta-blockers, ACE-inhibitors, angiotensin-receptors blockers
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description enalapril arm Enalapril treatment with enalapril
- Primary Outcome Measures
Name Time Method Incidence of chemotherapy-induced cardiotoxicity 12 month period
- Secondary Outcome Measures
Name Time Method Major adverse cardiac events, including death. 12 month period
Trial Locations
- Locations (1)
European Institute of Oncology
🇮🇹Milan, Italy